Welcome to our dedicated page for Heron Therapeutics news (Ticker: $HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Heron Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Heron Therapeutics's position in the market.
Heron Therapeutics, Inc. (Nasdaq: HRTX) reported strong financial results for Q1 2024, including a 17% increase in Net Product Sales to $34.7 million and a significant improvement in Gross Margin to 76%. The company also announced a partnership with CrossLink Life Sciences, to boost ZYNRELEF® promotional efforts and FDA approval for an expanded indication for ZYNRELEF. Heron will host its first Investor Day event on May 15, 2024, in New York. The company reaffirmed its financial guidance for 2024, expecting promising growth across its Acute Care and Oncology franchises.
